Recessive Dystrophic Epidermolysis Bullosa Clinical Trial
Official title:
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.
Thirty-one (31) participants with DEB, aged 6 months or older at time of consent were enrolled for this Phase III study. The trial duration for each subject was about 6 months, with administration occurring once weekly. A Safety Follow-up Visit occurring 30 days from the date of final treatment with the Investigational Product also occurred. Each subject provided one pair of primary target wounds, with one wound from each pair randomized to be treated with B-VEC and the other wound with placebo. In addition to the primary target wound pair(s), additional wounds (secondary wounds) were selected to be treated with B-VEC. Throughout the study, participants complete questionnaires, had images captured of their study wounds, underwent physical exams, had vital signs and safety labs monitored. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02493816 -
Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
| Completed |
NCT04599881 -
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 2 | |
| Completed |
NCT04520022 -
Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03632265 -
Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Recruiting |
NCT05944250 -
A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients
|
N/A | |
| Recruiting |
NCT04917887 -
Long-Term Follow-up Protocol
|
||
| Completed |
NCT04917874 -
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Not yet recruiting |
NCT04285294 -
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
|
||
| Active, not recruiting |
NCT04213261 -
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Active, not recruiting |
NCT02323789 -
Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01874769 -
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
N/A | |
| Recruiting |
NCT03392909 -
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
| Completed |
NCT03752905 -
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02984085 -
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.
|
Phase 1/Phase 2 | |
| Completed |
NCT04227106 -
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 3 | |
| Completed |
NCT02698735 -
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03012191 -
Gentamicin for RDEB
|
Phase 1/Phase 2 | |
| Completed |
NCT03529877 -
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
| Completed |
NCT05143190 -
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
|
Phase 2 | |
| Recruiting |
NCT04177498 -
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
|
Early Phase 1 |